XenTech Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 37

Employees

  • Latest Deal Type
  • 2ndary - Private

XenTech General Information

Description

Provider of patient-derived tumor xenograft models designed to foster therapeutic development in oncology. The company's models focus on the pre-clinical evaluation of oncology therapeutics by offering translational platforms, enabling doctors to avail of relevant tumor models, and addressing tomorrow's needs in preclinical oncology research.

Contact Information

Website
www.xentech.eu
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1-7 Imp. Alexis Trinquet
  • 91000 Evry
  • France
+33 01
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 1-7 Imp. Alexis Trinquet
  • 91000 Evry
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XenTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 01-Aug-2022 Completed Generating Revenue
5. Grant 16-Mar-2009 Completed Generating Revenue
4. Seed Round 31-Oct-2008 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2006 Completed Startup
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view XenTech’s complete valuation and funding history, request access »

XenTech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view XenTech’s complete cap table history, request access »

XenTech Patents

XenTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021508835-A Method based on detection of rad51 phoci in tumor cells Active 21-Dec-2017
JP-7324769-B2 Methods based on detection of rad51 foci in tumor cells Active 21-Dec-2017
AU-2018387831-A1 Methods based on the detection of rad51 foci in tumor cells Active 21-Dec-2017
AU-2018387831-B2 Methods based on the detection of rad51 foci in tumor cells Active 21-Dec-2017
CA-3086794-A1 Methods based on the detection of rad51 foci in tumor cells Pending 21-Dec-2017 G01N33/575
To view XenTech’s complete patent history, request access »

XenTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XenTech FAQs

  • When was XenTech founded?

    XenTech was founded in 2006.

  • Where is XenTech headquartered?

    XenTech is headquartered in Evry, France.

  • What is the size of XenTech?

    XenTech has 37 total employees.

  • What industry is XenTech in?

    XenTech’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is XenTech a private or public company?

    XenTech is a Private company.

  • What is XenTech’s current revenue?

    The current revenue for XenTech is .

  • How much funding has XenTech raised over time?

    XenTech has raised $794K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process